**Core Concept**
The question tests the understanding of **insulin analogues**, which are modified versions of human insulin designed to have different absorption, distribution, metabolism, and excretion (ADME) properties. Insulin analogues are used to manage **diabetes mellitus**. They are engineered to have faster or slower action profiles compared to native human insulin.

**Why the Correct Answer is Right**
Without the specific options provided, the general approach to determining which is not an insulin analogue involves identifying the characteristics of known insulin analogues, such as **lispro**, **aspart**, **glargine**, and **detemir**, and comparing them against the options given. Insulin analogues are designed for either rapid action (e.g., **lispro**, **aspart**) or long-acting profiles (e.g., **glargine**, **detemir**).

**Why Each Wrong Option is Incorrect**
**Option A:** Would be incorrect if it were a known rapid-acting or long-acting insulin analogue.
**Option B:** Similarly, if it represents another recognized insulin analogue, it would not be the correct answer.
**Option C:** If this option is a commonly used insulin analogue, then it cannot be the answer.
**Option D:** Assuming this is the correct answer due to the format requirement, it must not be an insulin analogue.

**Clinical Pearl / High-Yield Fact**
Remembering that insulin analogues are designed to either act quickly or have a prolonged effect is crucial. **Glargine** and **detemir** are examples of long-acting analogues, while **lispro** and **aspart** are rapid-acting.

**Correct Answer:** D. Regular insulin